By Cecilia Butini
Merck KGaA said Wednesday that it would invest 59 million euros ($69.5 million) in expanding its manufacturing capabilities, and capacity for high-potent active pharmaceutical ingredients and antibody-drug conjugates at its U.S. facility near Madison, Wisc.
The German pharmaceuticals and chemicals company said the investment would allow manufacturing of compounds for therapies which have the potential to treat cancer, and it would create roughly 50 full-time jobs starting in 2021.
Completion of the expansion--which consists of a 6,500-square-meter commercial building--is expected by mid-2022, the company said.
Write to Cecilia Butini at firstname.lastname@example.org